Orphan GPR146: an alternative therapeutic pathway to achieve cholesterol homeostasis?

Trends Endocrinol Metab. 2022 May 9:S1043-2760(22)00065-0. doi: 10.1016/j.tem.2022.04.008. Online ahead of print.ABSTRACTAtherosclerosis predisposes to myriad cardiovascular complications, including myocardial infarction and stroke. Statins have revolutionised cholesterol management but they do not work for all patients, particularly those with familial hypercholesterolaemia (FH). Genome-wide association studies have linked SNPs at orphan G protein-coupled receptor 146 (GPR146) to human atherosclerosis but how GPR146 influences serum cholesterol homeostasis was only recently described. Gpr146 deletion in mice reduces serum cholesterol and atherosclerotic plaque burden, confirming GPR146 as a potential therapeutic target for managing circulating cholesterol. Critically, this effect was independent of the low-density lipoprotein receptor. While still an orphan, the activation of GPR146 by serum suggests identification of its endogenous ligand is tantalisingly close. Herein, we discuss the evidence for GPR146 inhibition as a treatment for atherosclerosis.PMID:35550855 | DOI:10.1016/j.tem.2022.04.008
Source: Trends in Endocrinology and Metabolism: TEM - Category: Endocrinology Authors: Source Type: research